TransCode Therapeutics, Inc. Announces Closing of Public Offering Boston, MA — July 24, 2024 — TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (“TransCode” or the “Company”), a clinical-stage RNA oncology company committed to

TransCode Therapeutics, Inc. Announces Pricing of Public Offering Boston, MA — July 22, 2024 — TransCode Therapeutics, Inc. (Nasdaq: RNAZ), (“TransCode” or the “Company”), a clinical-stage RNA oncology company committed t

TransCode Therapeutics, Inc. Announces Proposed Public Offering of Common Stock Boston, MA – July 22, 2024 – TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (“TransCode” or the “Company”), a clinical-stage RNA oncology company committed t

Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements

TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors